Table 3. Patients' characteristics and... | American Society of Hematology

Table 3.

Patients' characteristics and their association with hemorrhagic cystitis on univariate analysis

	No. patients	HC (%)	Hazard ratio	95% CI	P
HSCT donor type
MRD	32	5 (16)	Ref	—	—
MM related	20	6 (30)	2	0.6-6.7	.2
MUD	38	15 (40)	2.9	1.0-7.9	.04
Patient age^*
25 or younger	45	18 (40)	2.5	1.1-5.8	.03
Older than 25	45	8 (17)	Ref	0.2-0.9	.03
Disease status (all patients)^*
Complete remission	61	22 (36)	Ref	—	—
No remission	29	4 (14)	0.4	0.1-1.1	.09
ATG in the conditioning regimen^*,†
Yes	26	9 (35)	0.9	0.4-2.2	.9
No	32	12 (38)	Ref
GVHD prophylaxis^*,†
Intense	31	13 (42)	1.7	0.7-4.1	.3
Standard	27	8 (30)	Ref	—	—
Conditioning regimen (MRD)
VP16 - Yes	18	3	1.4	0.2-8.3	.7
VP16 - No	14	2	Ref	—	—
Cyclophosphamide containing regimen (MRD and MUD)
Yes	65	18 (28)	0.7	0.16-3	.6
No	5	2 (40)	Ref	—	—
Source of CD34 (MRD)
BM	18	3 (17)	1.4	0.2-8.4	.7
PBSC	14	2 (14)	Ref	—	—
Donor's age^*
33 or younger	50	17 (34)	Ref	—	—
Older than 33	40	9 (22)	0.6	0.3-1.4	.3
Grade II-IV aGVHD^*,‡	27	‡	1.5	0.5-4.3	.4
Steroid use^*,‡	‡	‡	1.5	0.5-4.3	.4
Platelet recovery^*,‡	‡	‡	0.9	0.3-2.5	.8
Mortality with HC^*,‡	‡	‡	0.8	0.7-2	.5

	No. patients	HC (%)	Hazard ratio	95% CI	P
HSCT donor type
MRD	32	5 (16)	Ref	—	—
MM related	20	6 (30)	2	0.6-6.7	.2
MUD	38	15 (40)	2.9	1.0-7.9	.04
Patient age^*
25 or younger	45	18 (40)	2.5	1.1-5.8	.03
Older than 25	45	8 (17)	Ref	0.2-0.9	.03
Disease status (all patients)^*
Complete remission	61	22 (36)	Ref	—	—
No remission	29	4 (14)	0.4	0.1-1.1	.09
ATG in the conditioning regimen^*,†
Yes	26	9 (35)	0.9	0.4-2.2	.9
No	32	12 (38)	Ref
GVHD prophylaxis^*,†
Intense	31	13 (42)	1.7	0.7-4.1	.3
Standard	27	8 (30)	Ref	—	—
Conditioning regimen (MRD)
VP16 - Yes	18	3	1.4	0.2-8.3	.7
VP16 - No	14	2	Ref	—	—
Cyclophosphamide containing regimen (MRD and MUD)
Yes	65	18 (28)	0.7	0.16-3	.6
No	5	2 (40)	Ref	—	—
Source of CD34 (MRD)
BM	18	3 (17)	1.4	0.2-8.4	.7
PBSC	14	2 (14)	Ref	—	—
Donor's age^*
33 or younger	50	17 (34)	Ref	—	—
Older than 33	40	9 (22)	0.6	0.3-1.4	.3
Grade II-IV aGVHD^*,‡	27	‡	1.5	0.5-4.3	.4
Steroid use^*,‡	‡	‡	1.5	0.5-4.3	.4
Platelet recovery^*,‡	‡	‡	0.9	0.3-2.5	.8
Mortality with HC^*,‡	‡	‡	0.8	0.7-2	.5

Ref indicates reference group.—indicates reference value.

Data was analyzed excluding recipients of UCB.

Intense GVHD prophylaxis, including ATG in the conditioning regimen: analysis included MUDs and MM rel.

Time-dependent variable.